Quarterly Financial Results
Laurus Labs Q1 FY27 Results: Net Profit Jumps 126% as Revenue Crosses ₹2,000 Crore on Strong CDMO Growth
NSE
LAURUSLABS
BSE
540222
- Laurus Labs delivered its strongest quarterly performance with revenue crossing ₹2,000 crore for the first time.
- The company reported robust growth in profitability led by higher CDMO revenues, expanding margins, and improved operating leverage.
- Net profit more than doubled while EBITDA margin crossed 31%, reflecting a favourable business mix and continued execution across its pharmaceutical businesses.
PRICE-SENSITIVE TRIGGER
Event: Laurus Labs announced its Q1 FY27 standalone and consolidated financial results along with an investor presentation highlighting record revenue, margin expansion, and continued investment in manufacturing capacity and advanced technologies.
Type: Quarterly Financial Results
Impact: Positive
Immediate Effect: The company reported record quarterly revenue, EBITDA and net profit, supported by exceptional growth in its CDMO business, improved gross margins, and strong operational efficiency.
Metrics:
Financial Metrics:
- Revenue: ₹2,026 crore (▲29% YoY, ▲12% QoQ)
- Gross Margin: 62.7% (up 330 bps YoY)
- EBITDA: ₹644 crore (▲66% YoY, ▲23% QoQ)
- EBITDA Margin: 31.8% (up 700 bps YoY)
- Net Profit: ₹368 crore (▲126% YoY, ▲32% QoQ)
- Net Profit Margin: 18.2%
- EPS: ₹6.8 (▲127% YoY)
- R&D Spend: ₹118 crore (5.8% of revenue)
- Q1 CAPEX: ₹394 crore (19% of revenue)
Highlight:
- Laurus Labs reported its highest-ever quarterly revenue, EBITDA, and net profit, with margin expansion driven by a stronger CDMO business mix and operating leverage.
What Happened ?
Laurus Labs delivered a record financial performance during Q1 FY27 as strong execution across its Contract Development and Manufacturing Organization (CDMO) business significantly boosted revenue and profitability.
The Affordable Medicines segment maintained stable growth despite a challenging global environment, while the CDMO business benefited from higher commercial supplies and steady progress in late-stage customer projects. Improved product mix and operating efficiency resulted in substantial expansion in gross and EBITDA margins.
key details
Business Performance:
- Revenue crossed ₹2,000 crore for the first time.
- CDMO revenue increased 67% YoY to ₹870 crore.
- Affordable Medicines business grew 10% YoY to ₹1,156 crore.
- Small Molecules CDMO business expanded 69% YoY.
- Formulations (FDF) revenue increased 22% YoY.
- Gross margin improved to 62.7% due to a better product and business mix.
- EBITDA margin expanded to 31.8% through operating leverage.
Note:
- The quarter demonstrates Laurus Labs’ increasing contribution from higher-margin CDMO operations while maintaining steady performance in its core generics business.
Segment Performance:
CDMO
The CDMO business remained the primary growth driver during the quarter.
- Revenue increased 67% YoY to ₹870 crore.
- Strong commercial supplies supported higher utilization.
- More than 125 active customer projects remain under development.
- Capacity expansion continues across API, peptides and advanced technologies.
Affordable Medicines
The Affordable Medicines segment continued delivering stable growth.
- Revenue reached ₹1,156 crore, up 10% YoY.
- FDF business grew 22% YoY.
- API revenue remained broadly stable.
- Growth supported by product launches, healthy order book and expanding presence in emerging markets.
Operations & Expansion:
Laurus Labs continued investing aggressively in future growth opportunities.
Expansion Highlights
- Q1 FY27 CAPEX stood at ₹394 crore.
- More than 85% of total CAPEX is focused on growth projects.
- Continued investments across:
- Small Molecule APIs
- Peptides
- Fermentation
- Gene Therapy
- Antibody Drug Conjugates (ADC)
- Expansion projects are progressing across manufacturing facilities in Visakhapatnam, Hyderabad, Bengaluru and Mumbai.
- Total manufacturing network now includes 15 manufacturing assets and 6 R&D facilities.
ESG & Sustainability:
Laurus Labs continued strengthening its sustainability initiatives.
Highlights:
- Science Based Targets Initiative (SBTi) validated near-term emissions reduction targets.
- Targeting over 50% renewable electricity usage by 2031.
- S&P Global ESG Score of 81/100.
- Continued recognition through EcoVadis, MSCI ESG Ratings and other sustainability platforms.
Risk Analysis
Summary:
- While Laurus Labs delivered exceptional quarterly performance, future earnings remain dependent on execution of CDMO commercial projects, demand from global pharmaceutical customers, regulatory compliance, and successful commissioning of expansion projects.
Key Risks:
- Delay in commercialization of late-stage CDMO projects.
- Regulatory inspections across manufacturing facilities.
- Global pharmaceutical pricing pressure.
- Currency fluctuations impacting export earnings.
- Execution risk related to ongoing expansion projects.
Worst Case:
- Delays in commercial CDMO orders, slower customer demand or regulatory setbacks could moderate revenue growth and reduce operating leverage over future quarters.
Risk Level: Medium
Company Commentary
- Q1 FY27 marked another quarter of strong execution with record financial performance.
- CDMO business continues to witness healthy commercial momentum.
- Affordable Medicines business remains resilient despite global macro challenges.
- Manufacturing expansion across advanced technologies continues as planned.
- The company remains focused on long-term growth through capacity expansion, customer diversification and investment in next-generation pharmaceutical technologies.
Official Exchange Filing: Laurus Labs Limited
